source name	characteristics[organism]	characteristics[organism part]	characteristics[individual]	characteristics[cell type]	characteristics[ancestry category]	characteristics[age]	characteristics[sex]	characteristics[developmental stage]	characteristics[disease]	characteristics[depletion]	characteristics[biological replicate]	characteristics[sampling time]	assay name	technology type	comment[data file]	comment[file uri]	comment[fraction identifier]	comment[fractionation method]	comment[label]	comment[technical replicate]	comment[cleavage agent details]	comment[cleavage agent details]	comment[ms2 mass analyzer]	comment[instrument]	comment[separation]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[dissociation method]	comment[collision energy]	comment[precursor mass tolerance]	comment[fragment mass tolerance]	factor value[sampling time]
1 plasma at -8 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_1_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
1 plasma at 0 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_1_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
1 plasma at 4 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_1_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
1 plasma at 13 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_1_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
1 plasma at 26 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_1_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
1 plasma at 39 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_1_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
1 plasma at 52 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_1_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
1 plasma at -8 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_1_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
1 plasma at 0 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_1_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
1 plasma at 4 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_1_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
1 plasma at 13 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_1_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
1 plasma at 26 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150708_qep1_lc7_phge_sa_plate1c_1_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
1 plasma at 39 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_1_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
1 plasma at 52 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_1_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
1 plasma at -8 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_1_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
1 plasma at 0 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_1_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
1 plasma at 4 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150805_qep1_lc7_phge_sa_plate1d_1_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
1 plasma at 13 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_1_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
1 plasma at 26 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_1_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
1 plasma at 39 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_1_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
1 plasma at 52 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_1_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
1 plasma at -8 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_1_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
1 plasma at 0 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_1_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
1 plasma at 4 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_1_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
1 plasma at 13 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_1_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
1 plasma at 26 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_1_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
1 plasma at 39 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_1_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
1 plasma at 52 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_1_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
2 plasma at -8 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_02_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
2 plasma at 0 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_02_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
2 plasma at 4 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_02_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
2 plasma at 13 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_02_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
2 plasma at 26 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_02_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
2 plasma at 39 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_02_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
2 plasma at 52 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_02_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
2 plasma at -8 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_02_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
2 plasma at 0 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_02_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
2 plasma at 4 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_02_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
2 plasma at 13 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_02_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
2 plasma at 26 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150708_qep1_lc7_phge_sa_plate1c_02_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
2 plasma at 39 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_02_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
2 plasma at 52 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_02_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
2 plasma at -8 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_02_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
2 plasma at 0 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_02_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
2 plasma at 4 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150805_qep1_lc7_phge_sa_plate1d_02_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
2 plasma at 13 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_02_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
2 plasma at 26 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_02_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
2 plasma at 39 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_02_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
2 plasma at 52 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_02_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
2 plasma at -8 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_02_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
2 plasma at 0 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_02_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
2 plasma at 4 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_02_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
2 plasma at 13 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_02_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
2 plasma at 26 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_02_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
2 plasma at 39 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_02_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
2 plasma at 52 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_02_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
3 plasma at -8 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4b_03_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
3 plasma at 0 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4b_03_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
3 plasma at 4 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4b_03_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
3 plasma at 13 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4b_03_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
3 plasma at 26 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4b_03_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
3 plasma at 39 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4b_03_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
3 plasma at 52 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4b_03_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
3 plasma at -8 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4e_03_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
3 plasma at 0 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4e_03_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
3 plasma at 4 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4e_03_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
3 plasma at 13 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4e_03_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
3 plasma at 26 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4e_03_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
3 plasma at 39 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4e_03_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
3 plasma at 52 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4e_03_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
3 plasma at -8 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150824_qep1_lc7_phge_sa_plate4d_03_1	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
3 plasma at 0 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150824_qep1_lc7_phge_sa_plate4d_03_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
3 plasma at 4 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150824_qep1_lc7_phge_sa_plate4d_03_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
3 plasma at 13 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150824_qep1_lc7_phge_sa_plate4d_03_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
3 plasma at 26 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150824_qep1_lc7_phge_sa_plate4d_03_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
3 plasma at 39 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150824_qep1_lc7_phge_sa_plate4d_03_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
3 plasma at 52 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150824_qep1_lc7_phge_sa_plate4d_03_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
3 plasma at -8 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate4c_03_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
3 plasma at 0 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc7_phge_sa_plate4c_03_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
3 plasma at 4 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150917_qep1_lc7_phge_sa_plate4c_03_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
3 plasma at 13 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150917_qep1_lc7_phge_sa_plate4c_03_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
3 plasma at 26 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc7_phge_sa_plate4c_03_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
3 plasma at 39 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150917_qep1_lc7_phge_sa_plate4c_03_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
3 plasma at 52 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150917_qep1_lc7_phge_sa_plate4c_03_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
5 plasma at -8 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_05_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
5 plasma at 0 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_05_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
5 plasma at 4 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_05_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
5 plasma at 13 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_05_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
5 plasma at 26 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150701_qep1_lc7_phge_sa_plate3a_05_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
5 plasma at 39 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_05_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
5 plasma at 52 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_05_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
5 plasma at 4 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150725_qep1_lc7_phge_sa_plate3b_05_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_05_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_05_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
5 plasma at 13 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150725_qep1_lc7_phge_sa_plate3b_05_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_05_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_05_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
5 plasma at 39 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150725_qep1_lc7_phge_sa_plate3b_05_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_05_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_05_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
5 plasma at 52 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150725_qep1_lc7_phge_sa_plate3b_05_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_05_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_05_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
5 plasma at -8 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_05_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
5 plasma at 0 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_05_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
5 plasma at 4 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_05_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
5 plasma at 13 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_05_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
5 plasma at 26 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_05_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
5 plasma at 52 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_05_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
5 plasma at -8 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_05_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
5 plasma at 4 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_05_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
5 plasma at 13 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150912_qep1_lc7_phge_sa_plate3d_05_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
5 plasma at 26 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_05_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
5 plasma at 39 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_05_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
5 plasma at 52 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_05_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
5 plasma at -8 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate3b_05_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_05_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_05_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
5 plasma at 0 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc7_phge_sa_plate3b_05_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_05_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_05_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
5 plasma at 26 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc7_phge_sa_plate3b_05_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_05_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_05_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
5 plasma at 39 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150917_qep1_lc7_phge_sa_plate3c_05_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3C_05_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3C_05_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
5 plasma at 0 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc8_phge_sa_plate3d_05_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate3D_05_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate3D_05_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
6 plasma at -8 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_06_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
6 plasma at 0 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_06_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
6 plasma at 4 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_06_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
6 plasma at 13 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_06_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
6 plasma at 26 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_06_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
6 plasma at 39 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_06_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
6 plasma at 52 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_06_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
6 plasma at -8 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_06_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
6 plasma at 0 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_06_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
6 plasma at 4 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_06_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
6 plasma at 13 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_06_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
6 plasma at 26 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_06_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
6 plasma at 39 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_06_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
6 plasma at 52 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_06_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
6 plasma at -8 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_06_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
6 plasma at 4 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_06_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
6 plasma at 13 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_06_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
6 plasma at 26 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_06_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
6 plasma at 39 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_06_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
6 plasma at 52 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_06_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
6 plasma at -8 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_06_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
6 plasma at 0 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_06_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
6 plasma at 4 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_06_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
6 plasma at 13 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_06_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
6 plasma at 26 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_06_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
6 plasma at 39 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_06_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
6 plasma at 52 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_06_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
6 plasma at 0 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc7_phge_sa_plate2c_06_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate2C_06_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate2C_06_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
7 plasma at -8 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_07_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
7 plasma at 0 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_07_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
7 plasma at 4 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_07_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
7 plasma at 13 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_07_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
7 plasma at 26 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_07_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
7 plasma at 39 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_07_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
7 plasma at 52 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_07_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
7 plasma at -8 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_07_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
7 plasma at 0 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_07_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
7 plasma at 4 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_07_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
7 plasma at 13 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_07_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
7 plasma at 26 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150708_qep1_lc7_phge_sa_plate1c_07_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
7 plasma at 39 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_07_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
7 plasma at 52 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_07_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
7 plasma at -8 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_07_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
7 plasma at 0 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_07_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
7 plasma at 13 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_07_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
7 plasma at 26 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_07_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
7 plasma at 39 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_07_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
7 plasma at 52 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_07_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
7 plasma at -8 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_07_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
7 plasma at 0 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_07_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
7 plasma at 4 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_07_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
7 plasma at 13 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_07_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
7 plasma at 26 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_07_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
7 plasma at 39 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_07_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
7 plasma at 52 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_07_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
7 plasma at 4 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150917_qep1_lc7_phge_sa_plate1d_07_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate1D_07_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate1D_07_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
8 plasma at -8 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_08_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
8 plasma at 0 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_08_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
8 plasma at 4 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_08_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
8 plasma at 13 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_08_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
8 plasma at 26 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_08_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
8 plasma at 39 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_08_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
8 plasma at 52 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_08_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
8 plasma at -8 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_08_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
8 plasma at 0 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_08_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
8 plasma at 4 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_08_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
8 plasma at 13 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_08_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
8 plasma at 26 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150708_qep1_lc7_phge_sa_plate1c_08_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
8 plasma at 39 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_08_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
8 plasma at 52 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_08_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
8 plasma at -8 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_08_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
8 plasma at 0 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_08_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
8 plasma at 4 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150805_qep1_lc7_phge_sa_plate1d_08_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
8 plasma at 13 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_08_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
8 plasma at 26 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_08_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
8 plasma at 39 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_08_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
8 plasma at 52 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_08_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
8 plasma at -8 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_08_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
8 plasma at 0 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_08_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
8 plasma at 4 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_08_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
8 plasma at 13 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_08_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
8 plasma at 26 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_08_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
8 plasma at 39 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_08_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
8 plasma at 52 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_08_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
9 plasma at -8 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4b_09_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
9 plasma at 0 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4b_09_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
9 plasma at 4 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4b_09_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
9 plasma at 13 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4b_09_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
9 plasma at 26 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4b_09_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
9 plasma at 39 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4b_09_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
9 plasma at 52 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4b_09_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
9 plasma at -8 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4e_09_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
9 plasma at 0 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4e_09_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
9 plasma at 4 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4e_09_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
9 plasma at 13 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4e_09_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
9 plasma at 26 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4e_09_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
9 plasma at 39 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4e_09_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
9 plasma at 52 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4e_09_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
9 plasma at -8 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150824_qep1_lc7_phge_sa_plate4d_09_1	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
9 plasma at 0 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150824_qep1_lc7_phge_sa_plate4d_09_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
9 plasma at 4 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150824_qep1_lc7_phge_sa_plate4d_09_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
9 plasma at 13 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150824_qep1_lc7_phge_sa_plate4d_09_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
9 plasma at 26 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150824_qep1_lc7_phge_sa_plate4d_09_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
9 plasma at 39 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150824_qep1_lc7_phge_sa_plate4d_09_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
9 plasma at 52 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150824_qep1_lc7_phge_sa_plate4d_09_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
9 plasma at -8 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate4c_09_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
9 plasma at 0 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc7_phge_sa_plate4c_09_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
9 plasma at 4 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150917_qep1_lc7_phge_sa_plate4c_09_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
9 plasma at 13 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150917_qep1_lc7_phge_sa_plate4c_09_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
9 plasma at 26 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc7_phge_sa_plate4c_09_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
9 plasma at 39 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150917_qep1_lc7_phge_sa_plate4c_09_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
9 plasma at 52 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150917_qep1_lc7_phge_sa_plate4c_09_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
10 plasma at -8 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_10_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
10 plasma at 0 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_10_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
10 plasma at 4 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_10_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
10 plasma at 13 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_10_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
10 plasma at 26 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150701_qep1_lc7_phge_sa_plate3a_10_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
10 plasma at 39 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_10_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
10 plasma at 52 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_10_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
10 plasma at 0 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_10_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_10_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_10_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
10 plasma at 4 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150725_qep1_lc7_phge_sa_plate3b_10_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_10_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_10_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
10 plasma at 13 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150725_qep1_lc7_phge_sa_plate3b_10_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_10_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_10_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
10 plasma at 26 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150725_qep1_lc7_phge_sa_plate3b_10_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_10_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_10_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
10 plasma at 39 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150725_qep1_lc7_phge_sa_plate3b_10_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_10_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_10_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
10 plasma at -8 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_10_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
10 plasma at 0 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_10_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
10 plasma at 4 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_10_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
10 plasma at 13 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_10_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
10 plasma at 26 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_10_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
10 plasma at 39 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150818_qep1_lc7_phge_sa_plate3c_10_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
10 plasma at 52 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_10_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
10 plasma at -8 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_10_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
10 plasma at 0 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_10_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
10 plasma at 4 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_10_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
10 plasma at 13 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150912_qep1_lc7_phge_sa_plate3d_10_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
10 plasma at 26 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_10_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
10 plasma at 39 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_10_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
10 plasma at 52 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_10_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
10 plasma at -8 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate3b_10_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_10_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_10_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
10 plasma at 52 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150917_qep1_lc7_phge_sa_plate3b_10_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_10_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_10_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
11 plasma at -8 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_11_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
11 plasma at 0 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_11_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
11 plasma at 4 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_11_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
11 plasma at 13 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_11_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
11 plasma at 26 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_11_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
11 plasma at 39 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_11_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
11 plasma at 52 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_11_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
11 plasma at -8 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_11_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
11 plasma at 0 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_11_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
11 plasma at 4 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_11_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
11 plasma at 13 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_11_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
11 plasma at 26 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150708_qep1_lc7_phge_sa_plate1c_11_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
11 plasma at 39 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_11_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
11 plasma at 52 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_11_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
11 plasma at -8 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_11_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
11 plasma at 0 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_11_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
11 plasma at 4 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150805_qep1_lc7_phge_sa_plate1d_11_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
11 plasma at 13 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_11_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
11 plasma at 26 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_11_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
11 plasma at 39 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_11_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
11 plasma at 52 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_11_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
11 plasma at -8 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_11_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
11 plasma at 0 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_11_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
11 plasma at 4 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_11_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
11 plasma at 13 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_11_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
11 plasma at 26 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_11_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
11 plasma at 39 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_11_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
11 plasma at 52 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_11_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
12 plasma at -8 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_12_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
12 plasma at 0 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_12_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
12 plasma at 13 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_12_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
12 plasma at 26 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_12_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
12 plasma at 39 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_12_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
12 plasma at 52 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_12_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
12 plasma at -8 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_12_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
12 plasma at 0 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_12_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
12 plasma at 4 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_12_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
12 plasma at 13 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_12_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
12 plasma at 26 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_12_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
12 plasma at 39 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_12_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
12 plasma at 52 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_12_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
12 plasma at -8 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_12_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
12 plasma at 0 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_12_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
12 plasma at 4 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_12_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
12 plasma at 13 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_12_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
12 plasma at 26 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_12_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
12 plasma at 39 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_12_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
12 plasma at 52 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_12_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
12 plasma at -8 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_12_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
12 plasma at 0 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_12_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
12 plasma at 4 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_12_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
12 plasma at 13 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_12_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
12 plasma at 26 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_12_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
12 plasma at 39 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_12_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
12 plasma at 52 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_12_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
12 plasma at 4 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150917_qep1_lc7_phge_sa_plate2a_12_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate2A_12_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate2A_12_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
14 plasma at -8 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4b_14_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
14 plasma at 0 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4b_14_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
14 plasma at 4 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4b_14_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
14 plasma at 13 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4b_14_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
14 plasma at 26 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4b_14_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
14 plasma at 39 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4b_14_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
14 plasma at 52 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4b_14_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
14 plasma at -8 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4e_14_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
14 plasma at 0 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4e_14_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
14 plasma at 4 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4e_14_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
14 plasma at 13 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4e_14_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
14 plasma at 26 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4e_14_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
14 plasma at 39 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4e_14_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
14 plasma at 52 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4e_14_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
14 plasma at -8 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150824_qep1_lc7_phge_sa_plate4d_14_1	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
14 plasma at 0 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150824_qep1_lc7_phge_sa_plate4d_14_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
14 plasma at 4 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150824_qep1_lc7_phge_sa_plate4d_14_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
14 plasma at 13 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150824_qep1_lc7_phge_sa_plate4d_14_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
14 plasma at 26 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150824_qep1_lc7_phge_sa_plate4d_14_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
14 plasma at 39 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150824_qep1_lc7_phge_sa_plate4d_14_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
14 plasma at 52 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150824_qep1_lc7_phge_sa_plate4d_14_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
14 plasma at -8 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate4c_14_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
14 plasma at 0 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc7_phge_sa_plate4c_14_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
14 plasma at 4 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150917_qep1_lc7_phge_sa_plate4c_14_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
14 plasma at 13 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150917_qep1_lc7_phge_sa_plate4c_14_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
14 plasma at 26 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc7_phge_sa_plate4c_14_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
14 plasma at 39 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150917_qep1_lc7_phge_sa_plate4c_14_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
14 plasma at 52 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150917_qep1_lc7_phge_sa_plate4c_14_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
15 plasma at -8 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_15_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
15 plasma at 0 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_15_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
15 plasma at 4 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_15_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
15 plasma at 13 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_15_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
15 plasma at 26 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150701_qep1_lc7_phge_sa_plate3a_15_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
15 plasma at 39 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_15_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
15 plasma at 52 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_15_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
15 plasma at -8 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150725_qep1_lc7_phge_sa_plate3b_15_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
15 plasma at 0 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_15_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
15 plasma at 4 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150725_qep1_lc7_phge_sa_plate3b_15_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
15 plasma at 13 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150725_qep1_lc7_phge_sa_plate3b_15_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
15 plasma at 26 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150725_qep1_lc7_phge_sa_plate3b_15_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
15 plasma at 39 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150725_qep1_lc7_phge_sa_plate3b_15_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
15 plasma at -8 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_15_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
15 plasma at 0 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_15_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
15 plasma at 4 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_15_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
15 plasma at 13 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_15_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
15 plasma at 26 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_15_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
15 plasma at 39 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150818_qep1_lc7_phge_sa_plate3c_15_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
15 plasma at 52 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_15_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
15 plasma at -8 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_15_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
15 plasma at 0 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_15_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
15 plasma at 4 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_15_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
15 plasma at 13 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150912_qep1_lc7_phge_sa_plate3d_15_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
15 plasma at 26 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_15_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
15 plasma at 39 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_15_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
15 plasma at 52 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_15_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
15 plasma at 52 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150917_qep1_lc7_phge_sa_plate3b_15_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_15_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_15_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
16 plasma at -8 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4b_16_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
16 plasma at 0 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4b_16_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
16 plasma at 4 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4b_16_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
16 plasma at 13 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4b_16_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
16 plasma at 26 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4b_16_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
16 plasma at 39 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4b_16_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
16 plasma at 52 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4b_16_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
16 plasma at -8 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4e_16_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
16 plasma at 0 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4e_16_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
16 plasma at 4 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4e_16_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
16 plasma at 13 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4e_16_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
16 plasma at 26 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4e_16_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
16 plasma at 39 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4e_16_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
16 plasma at 52 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4e_16_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
16 plasma at 0 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150824_qep1_lc7_phge_sa_plate4d_16_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
16 plasma at 4 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150824_qep1_lc7_phge_sa_plate4d_16_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
16 plasma at 13 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150824_qep1_lc7_phge_sa_plate4d_16_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
16 plasma at 26 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150824_qep1_lc7_phge_sa_plate4d_16_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
16 plasma at 39 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150824_qep1_lc7_phge_sa_plate4d_16_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
16 plasma at 52 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150824_qep1_lc7_phge_sa_plate4d_16_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
16 plasma at -8 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate4c_16_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
16 plasma at 0 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc7_phge_sa_plate4c_16_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
16 plasma at 4 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150917_qep1_lc7_phge_sa_plate4c_16_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
16 plasma at 13 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150917_qep1_lc7_phge_sa_plate4c_16_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
16 plasma at 26 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc7_phge_sa_plate4c_16_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
16 plasma at 39 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150917_qep1_lc7_phge_sa_plate4c_16_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
16 plasma at 52 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150917_qep1_lc7_phge_sa_plate4c_16_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
16 plasma at -8 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate4d_16_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4D_16_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4D_16_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
17 plasma at -8 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_17_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
17 plasma at 0 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_17_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
17 plasma at 4 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_17_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
17 plasma at 13 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_17_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
17 plasma at 26 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_17_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
17 plasma at 39 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_17_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
17 plasma at 52 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_17_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
17 plasma at -8 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_17_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
17 plasma at 0 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_17_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
17 plasma at 4 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_17_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
17 plasma at 13 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_17_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
17 plasma at 26 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_17_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
17 plasma at 39 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_17_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
17 plasma at 52 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_17_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
17 plasma at -8 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_17_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
17 plasma at 0 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_17_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
17 plasma at 4 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_17_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
17 plasma at 13 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_17_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
17 plasma at 26 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_17_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
17 plasma at 39 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_17_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
17 plasma at 52 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_17_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
17 plasma at -8 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_17_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
17 plasma at 0 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_17_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
17 plasma at 4 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_17_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
17 plasma at 13 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_17_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
17 plasma at 26 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_17_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
17 plasma at 39 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_17_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
17 plasma at 52 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_17_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
19 plasma at -8 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_19_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
19 plasma at 0 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_19_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
19 plasma at 4 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_19_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
19 plasma at 13 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_19_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
19 plasma at 26 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_19_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
19 plasma at 39 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_19_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
19 plasma at 52 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_19_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
19 plasma at -8 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_19_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
19 plasma at 0 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_19_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
19 plasma at 4 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_19_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
19 plasma at 13 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_19_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
19 plasma at 26 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150708_qep1_lc7_phge_sa_plate1c_19_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
19 plasma at 39 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_19_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
19 plasma at 52 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_19_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
19 plasma at -8 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_19_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
19 plasma at 0 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_19_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
19 plasma at 4 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150805_qep1_lc7_phge_sa_plate1d_19_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
19 plasma at 13 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_19_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
19 plasma at 26 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_19_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
19 plasma at 39 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_19_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
19 plasma at 52 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_19_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
19 plasma at -8 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_19_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
19 plasma at 0 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_19_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
19 plasma at 4 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_19_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
19 plasma at 13 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_19_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
19 plasma at 26 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_19_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
19 plasma at 39 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_19_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
19 plasma at 52 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_19_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
20 plasma at -8 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_20_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
20 plasma at 0 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_20_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
20 plasma at 4 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_20_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
20 plasma at 13 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_20_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
20 plasma at 26 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_20_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
20 plasma at 39 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_20_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
20 plasma at 52 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_20_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
20 plasma at -8 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_20_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
20 plasma at 0 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_20_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
20 plasma at 4 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_20_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
20 plasma at 13 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_20_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
20 plasma at 26 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_20_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
20 plasma at 39 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_20_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
20 plasma at 52 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_20_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
20 plasma at -8 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_20_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
20 plasma at 0 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_20_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
20 plasma at 4 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_20_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
20 plasma at 13 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_20_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
20 plasma at 26 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_20_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
20 plasma at 39 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_20_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
20 plasma at 52 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_20_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
20 plasma at -8 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_20_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
20 plasma at 0 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_20_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
20 plasma at 4 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_20_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
20 plasma at 13 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_20_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
20 plasma at 26 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_20_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
20 plasma at 39 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_20_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
20 plasma at 52 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_20_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
21 plasma at -8 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_21_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
21 plasma at 0 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_21_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
21 plasma at 4 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_21_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
21 plasma at 13 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_21_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
21 plasma at 26 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_21_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
21 plasma at 39 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_21_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
21 plasma at 52 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_21_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
21 plasma at -8 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_21_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
21 plasma at 0 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_21_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
21 plasma at 4 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_21_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
21 plasma at 13 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_21_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
21 plasma at 26 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_21_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
21 plasma at 39 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_21_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
21 plasma at 52 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_21_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
21 plasma at -8 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_21_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
21 plasma at 0 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_21_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
21 plasma at 4 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_21_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
21 plasma at 13 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_21_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
21 plasma at 26 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_21_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
21 plasma at 39 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_21_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
21 plasma at 52 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_21_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
21 plasma at -8 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_21_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
21 plasma at 0 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_21_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
21 plasma at 4 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_21_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
21 plasma at 13 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_21_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
21 plasma at 26 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_21_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
21 plasma at 39 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_21_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
21 plasma at 52 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_21_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
22 plasma at -8 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_22_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
22 plasma at 0 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_22_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
22 plasma at 4 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_22_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
22 plasma at 13 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_22_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
22 plasma at 26 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_22_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
22 plasma at 39 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_22_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
22 plasma at 52 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_22_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
22 plasma at -8 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_22_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
22 plasma at 0 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_22_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
22 plasma at 4 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_22_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
22 plasma at 13 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_22_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
22 plasma at 26 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_22_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
22 plasma at 39 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_22_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
22 plasma at 52 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_22_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
22 plasma at -8 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_22_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
22 plasma at 0 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_22_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
22 plasma at 4 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_22_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
22 plasma at 13 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_22_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
22 plasma at 26 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_22_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
22 plasma at 39 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_22_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
22 plasma at 52 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_22_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
22 plasma at -8 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_22_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
22 plasma at 0 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_22_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
22 plasma at 4 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_22_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
22 plasma at 13 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_22_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
22 plasma at 26 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_22_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
22 plasma at 39 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_22_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
22 plasma at 52 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_22_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
23 plasma at -8 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_23_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
23 plasma at 0 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_23_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
23 plasma at 4 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_23_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
23 plasma at 13 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_23_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
23 plasma at 26 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150701_qep1_lc7_phge_sa_plate3a_23_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
23 plasma at 39 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_23_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
23 plasma at 52 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_23_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
23 plasma at 0 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_23_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_23_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_23_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
23 plasma at 4 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150725_qep1_lc7_phge_sa_plate3b_23_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_23_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_23_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
23 plasma at 26 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150725_qep1_lc7_phge_sa_plate3b_23_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_23_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_23_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
23 plasma at 52 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150725_qep1_lc7_phge_sa_plate3b_23_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_23_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_23_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
23 plasma at -8 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_23_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
23 plasma at 0 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_23_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
23 plasma at 4 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_23_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
23 plasma at 13 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_23_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
23 plasma at 26 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_23_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
23 plasma at 39 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150818_qep1_lc7_phge_sa_plate3c_23_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
23 plasma at 52 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_23_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
23 plasma at -8 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_23_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
23 plasma at 0 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_23_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
23 plasma at 4 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_23_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
23 plasma at 13 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150912_qep1_lc7_phge_sa_plate3d_23_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
23 plasma at 26 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_23_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
23 plasma at 39 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_23_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
23 plasma at 52 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_23_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
23 plasma at -8 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate3b_23_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_23_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_23_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
23 plasma at 13 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150917_qep1_lc7_phge_sa_plate3b_23_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_23_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_23_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
23 plasma at 39 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150917_qep1_lc7_phge_sa_plate3b_23_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_23_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_23_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
24 plasma at -8 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_24_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_24_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_24_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
24 plasma at 0 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_24_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_24_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_24_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
24 plasma at -8 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_24_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_24_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_24_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
24 plasma at 0 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_24_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_24_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_24_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
24 plasma at -8 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_24_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_24_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_24_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
24 plasma at 0 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_24_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_24_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_24_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
24 plasma at -8 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_24_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_24_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_24_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
24 plasma at 0 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_24_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_24_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_24_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
25 plasma at 0 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_25_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_25_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_25_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
25 plasma at 4 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_25_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_25_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_25_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
25 plasma at 26 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_25_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_25_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_25_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
25 plasma at 39 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_25_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_25_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_25_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
25 plasma at 52 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_25_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_25_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_25_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
25 plasma at -8 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_25_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
25 plasma at 0 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_25_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
25 plasma at 4 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_25_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
25 plasma at 13 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_25_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
25 plasma at 26 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_25_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
25 plasma at 39 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_25_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
25 plasma at 52 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_25_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
25 plasma at -8 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_25_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
25 plasma at 0 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_25_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
25 plasma at 4 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_25_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
25 plasma at 13 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_25_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
25 plasma at 26 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_25_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
25 plasma at 39 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_25_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
25 plasma at 52 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_25_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
25 plasma at -8 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_25_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
25 plasma at 0 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_25_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
25 plasma at 4 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_25_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
25 plasma at 13 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_25_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
25 plasma at 26 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_25_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
25 plasma at 39 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_25_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
25 plasma at 52 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_25_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
25 plasma at -8 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate2a_25_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate2A_25_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate2A_25_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
25 plasma at 13 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150917_qep1_lc7_phge_sa_plate2a_25_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate2A_25_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate2A_25_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
26 plasma at -8 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_26_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
26 plasma at 0 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_26_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
26 plasma at 4 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_26_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
26 plasma at 13 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_26_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
26 plasma at 39 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_26_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
26 plasma at 52 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_26_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
26 plasma at -8 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150725_qep1_lc7_phge_sa_plate3b_26_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
26 plasma at 0 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_26_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
26 plasma at 4 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150725_qep1_lc7_phge_sa_plate3b_26_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
26 plasma at 13 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150725_qep1_lc7_phge_sa_plate3b_26_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
26 plasma at 39 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150725_qep1_lc7_phge_sa_plate3b_26_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
26 plasma at 52 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150725_qep1_lc7_phge_sa_plate3b_26_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
26 plasma at -8 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_26_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
26 plasma at 0 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_26_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
26 plasma at 4 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_26_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
26 plasma at 13 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_26_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
26 plasma at 26 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_26_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
26 plasma at 39 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150818_qep1_lc7_phge_sa_plate3c_26_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
26 plasma at 52 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_26_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
26 plasma at -8 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_26_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
26 plasma at 0 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_26_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
26 plasma at 4 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_26_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
26 plasma at 13 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150912_qep1_lc7_phge_sa_plate3d_26_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
26 plasma at 26 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_26_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
26 plasma at 39 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_26_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
26 plasma at 52 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_26_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
26 plasma at 26 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc7_phge_sa_plate3a_26_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3A_26_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3A_26_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
26 plasma at 26 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc7_phge_sa_plate3b_26_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_26_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_26_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
27 plasma at -8 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_27_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
27 plasma at 0 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_27_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
27 plasma at 4 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_27_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
27 plasma at 13 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_27_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
27 plasma at 26 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150701_qep1_lc7_phge_sa_plate3a_27_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
27 plasma at 39 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_27_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
27 plasma at 52 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_27_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
27 plasma at -8 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150725_qep1_lc7_phge_sa_plate3b_27_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
27 plasma at 0 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_27_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
27 plasma at 4 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150725_qep1_lc7_phge_sa_plate3b_27_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
27 plasma at 13 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150725_qep1_lc7_phge_sa_plate3b_27_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
27 plasma at 26 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150725_qep1_lc7_phge_sa_plate3b_27_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
27 plasma at 39 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150725_qep1_lc7_phge_sa_plate3b_27_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
27 plasma at 52 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150725_qep1_lc7_phge_sa_plate3b_27_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
27 plasma at -8 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_27_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
27 plasma at 0 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_27_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
27 plasma at 4 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_27_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
27 plasma at 13 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_27_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
27 plasma at 26 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_27_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
27 plasma at 39 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150818_qep1_lc7_phge_sa_plate3c_27_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
27 plasma at 52 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_27_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
27 plasma at -8 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_27_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
27 plasma at 0 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_27_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
27 plasma at 4 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_27_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
27 plasma at 13 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150912_qep1_lc7_phge_sa_plate3d_27_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
27 plasma at 26 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_27_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
27 plasma at 39 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_27_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
27 plasma at 52 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_27_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
28 plasma at -8 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_28_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
28 plasma at 0 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_28_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
28 plasma at 4 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_28_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
28 plasma at 13 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_28_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
28 plasma at 26 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_28_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
28 plasma at 39 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_28_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
28 plasma at 52 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_28_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
28 plasma at -8 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_28_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
28 plasma at 0 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_28_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
28 plasma at 4 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_28_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
28 plasma at 13 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_28_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
28 plasma at 39 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_28_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
28 plasma at 52 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_28_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
28 plasma at -8 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_28_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
28 plasma at 0 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_28_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
28 plasma at 4 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150805_qep1_lc7_phge_sa_plate1d_28_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
28 plasma at 13 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_28_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
28 plasma at 26 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_28_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
28 plasma at 39 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_28_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
28 plasma at 52 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_28_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
28 plasma at -8 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_28_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
28 plasma at 0 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_28_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
28 plasma at 4 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_28_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
28 plasma at 13 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_28_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
28 plasma at 26 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_28_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
28 plasma at 39 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_28_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
28 plasma at 52 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_28_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
28 plasma at 26 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc8_phge_sa_plate1c_28_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate1C_28_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate1C_28_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
29 plasma at -8 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_29_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
29 plasma at 0 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_29_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
29 plasma at 4 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_29_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
29 plasma at 13 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_29_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
29 plasma at 26 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_29_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
29 plasma at 39 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_29_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
29 plasma at 52 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_29_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
29 plasma at -8 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_29_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
29 plasma at 0 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_29_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
29 plasma at 4 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_29_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
29 plasma at 13 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_29_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
29 plasma at 26 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_29_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
29 plasma at 39 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_29_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
29 plasma at 52 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_29_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
29 plasma at -8 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_29_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
29 plasma at 0 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_29_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
29 plasma at 4 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_29_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
29 plasma at 13 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_29_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
29 plasma at 26 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_29_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
29 plasma at 39 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_29_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
29 plasma at 52 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_29_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
29 plasma at -8 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_29_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
29 plasma at 0 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_29_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
29 plasma at 4 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_29_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
29 plasma at 13 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_29_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
29 plasma at 26 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_29_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
29 plasma at 39 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_29_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
29 plasma at 52 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_29_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
30 plasma at -8 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_30_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
30 plasma at 0 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_30_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
30 plasma at 4 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_30_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
30 plasma at 13 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_30_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
30 plasma at 26 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_30_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
30 plasma at 39 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_30_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
30 plasma at 52 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_30_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
30 plasma at -8 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_30_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
30 plasma at 0 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_30_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
30 plasma at 4 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_30_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
30 plasma at 13 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_30_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
30 plasma at 26 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150708_qep1_lc7_phge_sa_plate1c_30_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
30 plasma at 39 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_30_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
30 plasma at 52 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_30_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
30 plasma at -8 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_30_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
30 plasma at 0 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_30_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
30 plasma at 4 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150805_qep1_lc7_phge_sa_plate1d_30_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
30 plasma at 13 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_30_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
30 plasma at 26 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_30_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
30 plasma at 39 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_30_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
30 plasma at 52 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_30_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
30 plasma at -8 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_30_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
30 plasma at 0 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_30_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
30 plasma at 4 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_30_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
30 plasma at 13 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_30_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
30 plasma at 26 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_30_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
30 plasma at 39 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_30_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
30 plasma at 52 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_30_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
31 plasma at -8 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_31_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_31_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_31_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
31 plasma at 0 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_31_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_31_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_31_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
31 plasma at -8 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_31_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_31_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_31_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
31 plasma at 0 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_31_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_31_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_31_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
31 plasma at -8 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_31_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_31_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_31_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
31 plasma at 0 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_31_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_31_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_31_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
31 plasma at -8 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_31_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_31_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_31_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
31 plasma at 0 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_31_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_31_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_31_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
33 plasma at -8 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_33_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_33_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_33_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
33 plasma at 0 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_33_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_33_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_33_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
33 plasma at -8 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150725_qep1_lc7_phge_sa_plate3b_33_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_33_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_33_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
33 plasma at 0 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_33_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_33_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_33_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
33 plasma at 0 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_33_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_33_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_33_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
33 plasma at -8 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_33_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_33_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_33_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
33 plasma at -8 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate3c_33_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3C_33_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3C_33_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
33 plasma at 0 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc7_phge_sa_plate3d_33_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3D_33_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3D_33_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
34 plasma at -8 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_34_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
34 plasma at 0 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_34_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
34 plasma at 4 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_34_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
34 plasma at 13 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_34_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
34 plasma at 26 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150701_qep1_lc7_phge_sa_plate3a_34_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
34 plasma at 39 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_34_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
34 plasma at 52 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_34_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
34 plasma at -8 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150725_qep1_lc7_phge_sa_plate3b_34_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_34_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_34_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
34 plasma at 0 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_34_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_34_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_34_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
34 plasma at 26 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150725_qep1_lc7_phge_sa_plate3b_34_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_34_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_34_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
34 plasma at 52 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150725_qep1_lc7_phge_sa_plate3b_34_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_34_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_34_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
34 plasma at -8 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_34_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
34 plasma at 0 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_34_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
34 plasma at 4 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_34_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
34 plasma at 13 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_34_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
34 plasma at 26 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_34_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
34 plasma at 39 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150818_qep1_lc7_phge_sa_plate3c_34_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
34 plasma at 52 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_34_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
34 plasma at -8 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_34_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
34 plasma at 0 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_34_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
34 plasma at 4 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_34_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
34 plasma at 13 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150912_qep1_lc7_phge_sa_plate3d_34_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
34 plasma at 26 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_34_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
34 plasma at 39 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_34_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
34 plasma at 52 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_34_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
34 plasma at 4 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150917_qep1_lc7_phge_sa_plate3b_34_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_34_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_34_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
34 plasma at 13 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150917_qep1_lc7_phge_sa_plate3b_34_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_34_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_34_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
34 plasma at 39 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150917_qep1_lc7_phge_sa_plate3b_34_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_34_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_34_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
35 plasma at -8 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_35_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_35_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_35_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
35 plasma at 0 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_35_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_35_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_35_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
35 plasma at 0 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_35_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_35_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_35_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
35 plasma at -8 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_35_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_35_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_35_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
35 plasma at 0 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_35_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_35_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_35_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
35 plasma at -8 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_35_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_35_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_35_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
35 plasma at 0 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_35_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_35_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_35_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
35 plasma at -8 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate3b_35_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_35_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_35_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
36 plasma at -8 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_36_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
36 plasma at 0 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_36_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
36 plasma at 4 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_36_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
36 plasma at 13 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_36_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
36 plasma at 26 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_36_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
36 plasma at 39 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_36_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
36 plasma at 52 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_36_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
36 plasma at -8 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_36_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
36 plasma at 0 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_36_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
36 plasma at 4 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_36_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
36 plasma at 13 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_36_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
36 plasma at 26 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_36_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
36 plasma at 39 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_36_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
36 plasma at 52 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_36_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
36 plasma at -8 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_36_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
36 plasma at 0 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_36_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
36 plasma at 4 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_36_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
36 plasma at 13 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_36_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
36 plasma at 26 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_36_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
36 plasma at 39 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_36_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
36 plasma at 52 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_36_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
36 plasma at -8 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_36_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
36 plasma at 0 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_36_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
36 plasma at 4 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_36_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
36 plasma at 13 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_36_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
36 plasma at 26 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_36_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
36 plasma at 39 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_36_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
36 plasma at 52 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_36_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
37 plasma at -8 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_37_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
37 plasma at 0 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_37_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
37 plasma at 4 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_37_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
37 plasma at 13 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_37_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
37 plasma at 26 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150701_qep1_lc7_phge_sa_plate3a_37_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
37 plasma at 39 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_37_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
37 plasma at 52 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_37_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
37 plasma at -8 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150725_qep1_lc7_phge_sa_plate3b_37_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
37 plasma at 0 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_37_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
37 plasma at 4 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150725_qep1_lc7_phge_sa_plate3b_37_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
37 plasma at 13 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150725_qep1_lc7_phge_sa_plate3b_37_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
37 plasma at 26 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150725_qep1_lc7_phge_sa_plate3b_37_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
37 plasma at 39 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150725_qep1_lc7_phge_sa_plate3b_37_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
37 plasma at 52 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150725_qep1_lc7_phge_sa_plate3b_37_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
37 plasma at -8 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_37_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
37 plasma at 0 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_37_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
37 plasma at 4 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_37_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
37 plasma at 13 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_37_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
37 plasma at 26 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_37_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
37 plasma at 52 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_37_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
37 plasma at -8 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_37_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
37 plasma at 0 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_37_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
37 plasma at 4 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_37_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
37 plasma at 13 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150912_qep1_lc7_phge_sa_plate3d_37_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
37 plasma at 26 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_37_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
37 plasma at 39 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_37_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
37 plasma at 52 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_37_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
37 plasma at 39 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150917_qep1_lc7_phge_sa_plate3c_37_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3C_37_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3C_37_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
38 plasma at -8 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_38_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
38 plasma at 0 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_38_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
38 plasma at 4 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_38_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
38 plasma at 13 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_38_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
38 plasma at 26 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_38_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
38 plasma at 39 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_38_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
38 plasma at 52 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_38_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
38 plasma at -8 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_38_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
38 plasma at 0 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_38_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
38 plasma at 4 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_38_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
38 plasma at 13 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_38_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
38 plasma at 26 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_38_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
38 plasma at 39 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_38_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
38 plasma at 52 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_38_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
38 plasma at -8 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_38_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
38 plasma at 0 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_38_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
38 plasma at 4 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_38_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
38 plasma at 13 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_38_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
38 plasma at 26 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_38_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
38 plasma at 39 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_38_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
38 plasma at 52 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_38_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
38 plasma at -8 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_38_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
38 plasma at 0 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_38_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
38 plasma at 4 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_38_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
38 plasma at 13 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_38_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
38 plasma at 26 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_38_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
38 plasma at 39 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_38_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
38 plasma at 52 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_38_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
39 plasma at -8 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_39_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
39 plasma at 0 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_39_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
39 plasma at 4 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_39_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
39 plasma at 13 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_39_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
39 plasma at 26 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150701_qep1_lc7_phge_sa_plate3a_39_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
39 plasma at 39 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_39_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
39 plasma at 52 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_39_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
39 plasma at 0 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_39_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
39 plasma at 4 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150725_qep1_lc7_phge_sa_plate3b_39_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
39 plasma at 13 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150725_qep1_lc7_phge_sa_plate3b_39_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
39 plasma at 26 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150725_qep1_lc7_phge_sa_plate3b_39_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
39 plasma at 39 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150725_qep1_lc7_phge_sa_plate3b_39_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
39 plasma at 52 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150725_qep1_lc7_phge_sa_plate3b_39_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
39 plasma at -8 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_39_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
39 plasma at 0 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_39_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
39 plasma at 4 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_39_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
39 plasma at 13 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_39_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
39 plasma at 26 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_39_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
39 plasma at 39 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150818_qep1_lc7_phge_sa_plate3c_39_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
39 plasma at 52 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_39_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
39 plasma at -8 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_39_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
39 plasma at 0 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_39_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
39 plasma at 4 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_39_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
39 plasma at 26 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_39_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
39 plasma at 39 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_39_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
39 plasma at 52 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_39_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
39 plasma at -8 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate3b_39_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_39_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_39_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
39 plasma at 13 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150917_qep1_lc7_phge_sa_plate3d_39_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3D_39_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3D_39_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
40 plasma at -8 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_40_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
40 plasma at 0 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_40_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
40 plasma at 4 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_40_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
40 plasma at 13 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_40_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
40 plasma at 26 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150701_qep1_lc7_phge_sa_plate3a_40_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
40 plasma at 39 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_40_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
40 plasma at 52 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_40_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
40 plasma at -8 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150725_qep1_lc7_phge_sa_plate3b_40_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
40 plasma at 0 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_40_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
40 plasma at 4 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150725_qep1_lc7_phge_sa_plate3b_40_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
40 plasma at 13 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150725_qep1_lc7_phge_sa_plate3b_40_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
40 plasma at 26 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150725_qep1_lc7_phge_sa_plate3b_40_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
40 plasma at 39 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150725_qep1_lc7_phge_sa_plate3b_40_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
40 plasma at 52 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150725_qep1_lc7_phge_sa_plate3b_40_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
40 plasma at -8 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_40_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
40 plasma at 0 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_40_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
40 plasma at 4 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_40_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
40 plasma at 13 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_40_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
40 plasma at 26 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_40_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
40 plasma at 39 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150818_qep1_lc7_phge_sa_plate3c_40_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
40 plasma at 52 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_40_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
40 plasma at -8 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_40_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
40 plasma at 0 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_40_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
40 plasma at 4 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_40_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
40 plasma at 13 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150912_qep1_lc7_phge_sa_plate3d_40_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
40 plasma at 26 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_40_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
40 plasma at 39 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_40_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
40 plasma at 52 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_40_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
41 plasma at -8 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_41_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
41 plasma at 0 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_41_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
41 plasma at 4 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_41_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
41 plasma at 13 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_41_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
41 plasma at 26 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_41_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
41 plasma at 39 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_41_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
41 plasma at 52 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_41_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
41 plasma at -8 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_41_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
41 plasma at 0 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_41_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
41 plasma at 4 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_41_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
41 plasma at 13 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_41_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
41 plasma at 26 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150708_qep1_lc7_phge_sa_plate1c_41_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
41 plasma at 39 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_41_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
41 plasma at 52 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_41_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
41 plasma at -8 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_41_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
41 plasma at 0 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_41_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
41 plasma at 4 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150805_qep1_lc7_phge_sa_plate1d_41_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
41 plasma at 13 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_41_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
41 plasma at 26 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_41_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
41 plasma at 39 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_41_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
41 plasma at 52 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_41_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
41 plasma at -8 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_41_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
41 plasma at 0 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_41_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
41 plasma at 4 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_41_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
41 plasma at 13 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_41_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
41 plasma at 26 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_41_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
41 plasma at 39 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_41_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
41 plasma at 52 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_41_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
42 plasma at -8 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_42_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
42 plasma at 0 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_42_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
42 plasma at 4 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_42_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
42 plasma at 13 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_42_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
42 plasma at 39 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_42_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
42 plasma at 52 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_42_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
42 plasma at -8 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_42_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
42 plasma at 0 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_42_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
42 plasma at 4 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_42_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
42 plasma at 13 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_42_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
42 plasma at 39 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_42_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
42 plasma at 52 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_42_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
42 plasma at -8 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_42_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
42 plasma at 0 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_42_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
42 plasma at 4 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_42_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
42 plasma at 13 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_42_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
42 plasma at 26 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_42_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
42 plasma at 39 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_42_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
42 plasma at 52 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_42_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
42 plasma at -8 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_42_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
42 plasma at 0 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_42_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
42 plasma at 4 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_42_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
42 plasma at 13 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_42_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
42 plasma at 26 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_42_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
42 plasma at 39 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_42_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
42 plasma at 52 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_42_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
42 plasma at 26 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc8_phge_sa_plate2a_42_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate2A_42_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate2A_42_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
42 plasma at 26 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc8_phge_sa_plate2b_42_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate2B_42_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate2B_42_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
43 plasma at -8 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4b_43_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
43 plasma at 0 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4b_43_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
43 plasma at 4 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4b_43_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
43 plasma at 13 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4b_43_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
43 plasma at 26 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4b_43_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
43 plasma at 39 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4b_43_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
43 plasma at 52 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4b_43_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
43 plasma at -8 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4e_43_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
43 plasma at 0 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4e_43_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
43 plasma at 4 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4e_43_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
43 plasma at 13 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4e_43_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
43 plasma at 26 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4e_43_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
43 plasma at 39 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4e_43_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
43 plasma at 52 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4e_43_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
43 plasma at -8 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150824_qep1_lc7_phge_sa_plate4d_43_1	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
43 plasma at 0 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150824_qep1_lc7_phge_sa_plate4d_43_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
43 plasma at 4 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150824_qep1_lc7_phge_sa_plate4d_43_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
43 plasma at 13 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150824_qep1_lc7_phge_sa_plate4d_43_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
43 plasma at 26 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150824_qep1_lc7_phge_sa_plate4d_43_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
43 plasma at 39 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150824_qep1_lc7_phge_sa_plate4d_43_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
43 plasma at 52 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150824_qep1_lc7_phge_sa_plate4d_43_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
43 plasma at -8 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate4c_43_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
43 plasma at 0 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc7_phge_sa_plate4c_43_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
43 plasma at 4 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150917_qep1_lc7_phge_sa_plate4c_43_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
43 plasma at 13 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150917_qep1_lc7_phge_sa_plate4c_43_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
43 plasma at 26 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc7_phge_sa_plate4c_43_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
43 plasma at 39 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150917_qep1_lc7_phge_sa_plate4c_43_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
43 plasma at 52 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150917_qep1_lc7_phge_sa_plate4c_43_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
44 plasma at 0 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_44_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
44 plasma at 4 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_44_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
44 plasma at 13 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_44_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
44 plasma at 26 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_44_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
44 plasma at 39 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_44_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
44 plasma at 52 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_44_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
44 plasma at 4 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_44_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_44_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_44_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
44 plasma at 13 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_44_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_44_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_44_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
44 plasma at 26 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150708_qep1_lc7_phge_sa_plate1c_44_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_44_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_44_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
44 plasma at 39 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_44_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_44_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_44_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
44 plasma at 52 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_44_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_44_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_44_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
44 plasma at 0 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_44_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
44 plasma at 4 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150805_qep1_lc7_phge_sa_plate1d_44_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
44 plasma at 13 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_44_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
44 plasma at 26 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_44_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
44 plasma at 39 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_44_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
44 plasma at 52 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_44_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
44 plasma at 0 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_44_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
44 plasma at 4 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_44_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
44 plasma at 13 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_44_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
44 plasma at 26 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_44_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
44 plasma at 39 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_44_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
44 plasma at 52 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_44_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
44 plasma at 0 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc8_phge_sa_plate1c_44_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate1C_44_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate1C_44_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
45 plasma at -8 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_45_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
45 plasma at 0 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_45_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
45 plasma at 4 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_45_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
45 plasma at 13 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_45_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
45 plasma at 26 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_45_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
45 plasma at 39 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_45_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
45 plasma at 52 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_45_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
45 plasma at -8 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_45_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
45 plasma at 0 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_45_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
45 plasma at 4 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_45_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
45 plasma at 13 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_45_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
45 plasma at 26 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150708_qep1_lc7_phge_sa_plate1c_45_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
45 plasma at 39 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_45_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
45 plasma at 52 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_45_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
45 plasma at -8 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_45_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
45 plasma at 0 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_45_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
45 plasma at 4 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150805_qep1_lc7_phge_sa_plate1d_45_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
45 plasma at 13 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_45_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
45 plasma at 26 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_45_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
45 plasma at 39 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_45_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
45 plasma at 52 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_45_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
45 plasma at -8 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_45_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
45 plasma at 0 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_45_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
45 plasma at 4 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_45_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
45 plasma at 13 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_45_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
45 plasma at 26 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_45_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
45 plasma at 39 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_45_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
45 plasma at 52 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_45_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
46 plasma at -8 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_46_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
46 plasma at 0 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_46_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
46 plasma at 4 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_46_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
46 plasma at 13 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_46_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
46 plasma at 26 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150701_qep1_lc7_phge_sa_plate3a_46_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
46 plasma at 39 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_46_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
46 plasma at 52 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_46_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
46 plasma at 0 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_46_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_46_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_46_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
46 plasma at 4 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150725_qep1_lc7_phge_sa_plate3b_46_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_46_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_46_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
46 plasma at 13 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150725_qep1_lc7_phge_sa_plate3b_46_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_46_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_46_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
46 plasma at 26 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150725_qep1_lc7_phge_sa_plate3b_46_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_46_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_46_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
46 plasma at 52 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150725_qep1_lc7_phge_sa_plate3b_46_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_46_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_46_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
46 plasma at -8 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_46_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
46 plasma at 0 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_46_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
46 plasma at 4 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_46_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
46 plasma at 13 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_46_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
46 plasma at 26 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_46_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
46 plasma at 39 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150818_qep1_lc7_phge_sa_plate3c_46_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
46 plasma at 52 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_46_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
46 plasma at -8 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_46_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
46 plasma at 0 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_46_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
46 plasma at 4 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_46_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
46 plasma at 13 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150912_qep1_lc7_phge_sa_plate3d_46_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
46 plasma at 26 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_46_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
46 plasma at 39 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_46_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
46 plasma at 52 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_46_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
46 plasma at -8 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate3b_46_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_46_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_46_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
46 plasma at 39 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150917_qep1_lc7_phge_sa_plate3b_46_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_46_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_46_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
47 plasma at -8 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_47_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
47 plasma at 0 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_47_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
47 plasma at 4 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_47_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
47 plasma at 13 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_47_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
47 plasma at 26 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_47_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
47 plasma at 39 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_47_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
47 plasma at 52 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_47_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
47 plasma at -8 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_47_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
47 plasma at 0 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_47_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
47 plasma at 4 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_47_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
47 plasma at 13 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_47_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
47 plasma at 26 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_47_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
47 plasma at 39 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_47_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
47 plasma at 52 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_47_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
47 plasma at -8 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_47_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
47 plasma at 0 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_47_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
47 plasma at 4 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_47_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
47 plasma at 13 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_47_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
47 plasma at 26 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_47_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
47 plasma at 39 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_47_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
47 plasma at 52 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_47_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
47 plasma at -8 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_47_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
47 plasma at 0 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_47_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
47 plasma at 4 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_47_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
47 plasma at 13 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_47_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
47 plasma at 26 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_47_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
47 plasma at 39 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_47_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
47 plasma at 52 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_47_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
48 plasma at -8 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_48_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
48 plasma at 0 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_48_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
48 plasma at 4 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150701_qep1_lc7_phge_sa_plate3a_48_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
48 plasma at 13 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150701_qep1_lc7_phge_sa_plate3a_48_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
48 plasma at 26 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150701_qep1_lc7_phge_sa_plate3a_48_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
48 plasma at 39 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150701_qep1_lc7_phge_sa_plate3a_48_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
48 plasma at 52 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150701_qep1_lc7_phge_sa_plate3a_48_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
48 plasma at -8 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150725_qep1_lc7_phge_sa_plate3b_48_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
48 plasma at 4 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150725_qep1_lc7_phge_sa_plate3b_48_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
48 plasma at 13 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150725_qep1_lc7_phge_sa_plate3b_48_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
48 plasma at 26 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150725_qep1_lc7_phge_sa_plate3b_48_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
48 plasma at 39 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150725_qep1_lc7_phge_sa_plate3b_48_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
48 plasma at 52 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150725_qep1_lc7_phge_sa_plate3b_48_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
48 plasma at -8 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_48_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
48 plasma at 0 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_48_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
48 plasma at 4 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150818_qep1_lc7_phge_sa_plate3c_48_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
48 plasma at 13 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150818_qep1_lc7_phge_sa_plate3c_48_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
48 plasma at 26 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150818_qep1_lc7_phge_sa_plate3c_48_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
48 plasma at 39 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150818_qep1_lc7_phge_sa_plate3c_48_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
48 plasma at 52 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150818_qep1_lc7_phge_sa_plate3c_48_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
48 plasma at -8 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_48_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
48 plasma at 0 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_48_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
48 plasma at 4 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150912_qep1_lc7_phge_sa_plate3d_48_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
48 plasma at 13 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150912_qep1_lc7_phge_sa_plate3d_48_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
48 plasma at 26 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150912_qep1_lc7_phge_sa_plate3d_48_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
48 plasma at 39 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150912_qep1_lc7_phge_sa_plate3d_48_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
48 plasma at 52 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150912_qep1_lc7_phge_sa_plate3d_48_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
48 plasma at 0 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc7_phge_sa_plate3b_48_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_48_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_48_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
49 plasma at -8 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_49_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_49_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_49_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
49 plasma at 0 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_49_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_49_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_49_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
49 plasma at -8 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_49_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_49_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_49_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
49 plasma at 0 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_49_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_49_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_49_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
49 plasma at -8 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_49_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_49_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_49_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
49 plasma at 0 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_49_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_49_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_49_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
49 plasma at -8 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_49_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_49_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_49_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
49 plasma at 0 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_49_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_49_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_49_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
50 plasma at -8 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_50_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_50_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_50_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
50 plasma at 0 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_50_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_50_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_50_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
50 plasma at -8 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_50_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_50_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_50_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
50 plasma at 0 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_50_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_50_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_50_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
50 plasma at -8 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_50_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_50_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_50_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
50 plasma at 0 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_50_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_50_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_50_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
50 plasma at -8 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_50_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_50_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_50_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
50 plasma at 0 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_50_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_50_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_50_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
51 plasma at -8 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_51_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_51_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_51_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
51 plasma at 0 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_51_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_51_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_51_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
51 plasma at -8 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150725_qep1_lc7_phge_sa_plate3b_51_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_51_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_51_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
51 plasma at 0 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_51_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_51_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_51_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
51 plasma at -8 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_51_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_51_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_51_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
51 plasma at 0 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_51_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_51_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_51_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
51 plasma at -8 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_51_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_51_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_51_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
51 plasma at 0 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc8_phge_sa_plate3d_51_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate3D_51_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate3D_51_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
52 plasma at -8 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150624_qep1_lc7_phge_sa_plate2a_52_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
52 plasma at 0 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150624_qep1_lc7_phge_sa_plate2a_52_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
52 plasma at 4 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150624_qep1_lc7_phge_sa_plate2a_52_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
52 plasma at 13 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150624_qep1_lc7_phge_sa_plate2a_52_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
52 plasma at 26 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150624_qep1_lc7_phge_sa_plate2a_52_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
52 plasma at 39 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150624_qep1_lc7_phge_sa_plate2a_52_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
52 plasma at 52 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150624_qep1_lc7_phge_sa_plate2a_52_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
52 plasma at -8 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150811_qep1_lc7_phge_sa_plate2b_52_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
52 plasma at 0 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150811_qep1_lc7_phge_sa_plate2b_52_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
52 plasma at 4 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150811_qep1_lc7_phge_sa_plate2b_52_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
52 plasma at 13 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150811_qep1_lc7_phge_sa_plate2b_52_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
52 plasma at 26 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150811_qep1_lc7_phge_sa_plate2b_52_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
52 plasma at 39 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150811_qep1_lc7_phge_sa_plate2b_52_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
52 plasma at 52 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150811_qep1_lc7_phge_sa_plate2b_52_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
52 plasma at -8 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150827_qep1_lc7_phge_sa_plate2c_52_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
52 plasma at 0 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150827_qep1_lc7_phge_sa_plate2c_52_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
52 plasma at 4 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150827_qep1_lc7_phge_sa_plate2c_52_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
52 plasma at 13 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150827_qep1_lc7_phge_sa_plate2c_52_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
52 plasma at 26 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150827_qep1_lc7_phge_sa_plate2c_52_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
52 plasma at 39 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150827_qep1_lc7_phge_sa_plate2c_52_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
52 plasma at 52 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150827_qep1_lc7_phge_sa_plate2c_52_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
52 plasma at -8 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150907_qep1_lc7_phge_sa_plate2d_52_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
52 plasma at 0 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150907_qep1_lc7_phge_sa_plate2d_52_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
52 plasma at 4 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150907_qep1_lc7_phge_sa_plate2d_52_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
52 plasma at 13 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150907_qep1_lc7_phge_sa_plate2d_52_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
52 plasma at 26 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150907_qep1_lc7_phge_sa_plate2d_52_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
52 plasma at 39 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150907_qep1_lc7_phge_sa_plate2d_52_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
52 plasma at 52 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150907_qep1_lc7_phge_sa_plate2d_52_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
53 plasma at -8 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_53_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_53_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_53_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
53 plasma at 0 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_53_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_53_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_53_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
53 plasma at -8 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_53_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_53_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_53_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
53 plasma at 0 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_53_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_53_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_53_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
53 plasma at -8 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_53_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_53_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_53_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
53 plasma at 0 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_53_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_53_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_53_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
53 plasma at -8 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_53_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_53_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_53_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
53 plasma at 0 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_53_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_53_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_53_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
54 plasma at -8 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150701_qep1_lc7_phge_sa_plate3a_54_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_54_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_54_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
54 plasma at 0 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150701_qep1_lc7_phge_sa_plate3a_54_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_54_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_54_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
54 plasma at -8 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150725_qep1_lc7_phge_sa_plate3b_54_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_54_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_54_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
54 plasma at 0 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150725_qep1_lc7_phge_sa_plate3b_54_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_54_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_54_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
54 plasma at -8 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150818_qep1_lc7_phge_sa_plate3c_54_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_54_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_54_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
54 plasma at 0 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150818_qep1_lc7_phge_sa_plate3c_54_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_54_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_54_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
54 plasma at -8 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150912_qep1_lc7_phge_sa_plate3d_54_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_54_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_54_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
54 plasma at 0 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150912_qep1_lc7_phge_sa_plate3d_54_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_54_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_54_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
57 plasma at -8 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150618_qep1_lc7_phge_sa_plate1b_57_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
57 plasma at 0 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150618_qep1_lc7_phge_sa_plate1b_57_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
57 plasma at 4 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150618_qep1_lc7_phge_sa_plate1b_57_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
57 plasma at 13 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150618_qep1_lc7_phge_sa_plate1b_57_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
57 plasma at 26 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150618_qep1_lc7_phge_sa_plate1b_57_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
57 plasma at 39 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150618_qep1_lc7_phge_sa_plate1b_57_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
57 plasma at 52 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150618_qep1_lc7_phge_sa_plate1b_57_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
57 plasma at -8 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150708_qep1_lc7_phge_sa_plate1c_57_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
57 plasma at 0 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150708_qep1_lc7_phge_sa_plate1c_57_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
57 plasma at 4 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150708_qep1_lc7_phge_sa_plate1c_57_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
57 plasma at 13 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150708_qep1_lc7_phge_sa_plate1c_57_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
57 plasma at 26 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150708_qep1_lc7_phge_sa_plate1c_57_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
57 plasma at 39 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150708_qep1_lc7_phge_sa_plate1c_57_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
57 plasma at 52 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150708_qep1_lc7_phge_sa_plate1c_57_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
57 plasma at -8 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150805_qep1_lc7_phge_sa_plate1d_57_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
57 plasma at 0 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150805_qep1_lc7_phge_sa_plate1d_57_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
57 plasma at 4 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150805_qep1_lc7_phge_sa_plate1d_57_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
57 plasma at 13 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150805_qep1_lc7_phge_sa_plate1d_57_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
57 plasma at 26 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150805_qep1_lc7_phge_sa_plate1d_57_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
57 plasma at 39 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150805_qep1_lc7_phge_sa_plate1d_57_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
57 plasma at 52 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150805_qep1_lc7_phge_sa_plate1d_57_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
57 plasma at -8 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150901_qep1_lc7_phge_sa_plate1e_57_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
57 plasma at 0 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150901_qep1_lc7_phge_sa_plate1e_57_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
57 plasma at 4 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150901_qep1_lc7_phge_sa_plate1e_57_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
57 plasma at 13 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150901_qep1_lc7_phge_sa_plate1e_57_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
57 plasma at 26 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150901_qep1_lc7_phge_sa_plate1e_57_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
57 plasma at 39 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150901_qep1_lc7_phge_sa_plate1e_57_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
57 plasma at 52 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150901_qep1_lc7_phge_sa_plate1e_57_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
58 plasma at -8 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4b_58_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
58 plasma at 0 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4b_58_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
58 plasma at 4 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4b_58_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
58 plasma at 13 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4b_58_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
58 plasma at 26 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4b_58_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
58 plasma at 39 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4b_58_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
58 plasma at 52 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4b_58_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
58 plasma at -8 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150731_qep1_lc7_phge_sa_plate4e_58_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
58 plasma at 0 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150731_qep1_lc7_phge_sa_plate4e_58_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
58 plasma at 4 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150731_qep1_lc7_phge_sa_plate4e_58_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
58 plasma at 13 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150731_qep1_lc7_phge_sa_plate4e_58_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
58 plasma at 26 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150731_qep1_lc7_phge_sa_plate4e_58_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
58 plasma at 39 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150731_qep1_lc7_phge_sa_plate4e_58_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
58 plasma at 52 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150731_qep1_lc7_phge_sa_plate4e_58_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
58 plasma at -8 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150824_qep1_lc7_phge_sa_plate4d_58_1	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
58 plasma at 0 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150824_qep1_lc7_phge_sa_plate4d_58_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
58 plasma at 4 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150824_qep1_lc7_phge_sa_plate4d_58_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
58 plasma at 13 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150824_qep1_lc7_phge_sa_plate4d_58_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
58 plasma at 26 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150824_qep1_lc7_phge_sa_plate4d_58_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
58 plasma at 39 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150824_qep1_lc7_phge_sa_plate4d_58_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
58 plasma at 52 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150824_qep1_lc7_phge_sa_plate4d_58_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
58 plasma at -8 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	-8W	20150917_qep1_lc7_phge_sa_plate4c_58_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
58 plasma at 0 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	0W	20150917_qep1_lc7_phge_sa_plate4c_58_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
58 plasma at 4 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	4W	20150917_qep1_lc7_phge_sa_plate4c_58_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
58 plasma at 13 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	13W	20150917_qep1_lc7_phge_sa_plate4c_58_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_4.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
58 plasma at 26 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	26W	20150917_qep1_lc7_phge_sa_plate4c_58_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_5.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
58 plasma at 39 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	39W	20150917_qep1_lc7_phge_sa_plate4c_58_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_6.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
58 plasma at 52 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	1	52W	20150917_qep1_lc7_phge_sa_plate4c_58_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_7.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
F1 plasma at not applicable weeks	Homo sapiens	blood plasma	F1	not applicable	not available	not available	female	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f1_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F1 plasma at not applicable weeks	Homo sapiens	blood plasma	F1	not applicable	not available	not available	female	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f1_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F1 plasma at not applicable weeks	Homo sapiens	blood plasma	F1	not applicable	not available	not available	female	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f1_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F2 plasma at not applicable weeks	Homo sapiens	blood plasma	F2	not applicable	not available	not available	female	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f2_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F2 plasma at not applicable weeks	Homo sapiens	blood plasma	F2	not applicable	not available	not available	female	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f2_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F2 plasma at not applicable weeks	Homo sapiens	blood plasma	F2	not applicable	not available	not available	female	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f2_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F3 plasma at not applicable weeks	Homo sapiens	blood plasma	F3	not applicable	not available	not available	female	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f3_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F3 plasma at not applicable weeks	Homo sapiens	blood plasma	F3	not applicable	not available	not available	female	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f3_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F3 plasma at not applicable weeks	Homo sapiens	blood plasma	F3	not applicable	not available	not available	female	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f3_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M1 plasma at not applicable weeks	Homo sapiens	blood plasma	M1	not applicable	not available	not available	male	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m1_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M1 plasma at not applicable weeks	Homo sapiens	blood plasma	M1	not applicable	not available	not available	male	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m1_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M1 plasma at not applicable weeks	Homo sapiens	blood plasma	M1	not applicable	not available	not available	male	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m1_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M2 plasma at not applicable weeks	Homo sapiens	blood plasma	M2	not applicable	not available	not available	male	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m2_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M2 plasma at not applicable weeks	Homo sapiens	blood plasma	M2	not applicable	not available	not available	male	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m2_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M2 plasma at not applicable weeks	Homo sapiens	blood plasma	M2	not applicable	not available	not available	male	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m2_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M3 plasma at not applicable weeks	Homo sapiens	blood plasma	M3	not applicable	not available	not available	male	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m3_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_1.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M3 plasma at not applicable weeks	Homo sapiens	blood plasma	M3	not applicable	not available	not available	male	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m3_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_2.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M3 plasma at not applicable weeks	Homo sapiens	blood plasma	M3	not applicable	not available	not available	male	not available	uninfected	depleted fraction	1	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m3_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_3.raw	https://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
